The funding committees for the NIHR Invention for Innovation (i4i) Programme are multidisciplinary, comprising academic, clinical and commercial experts, as well as patient and public members.
| Name | Position | Organisation |
|---|---|---|
| Professor David Nutt (Chair) | Professor of Neuropsychopharmacology | Imperial College London |
| Professor Celia Morgan (Deputy Chair) | Professor of Psychopharmacology | Exeter University |
| Ms Jenny Chong | Non-Executive Director | Medway Innovation Institute |
| Professor Karen Ersche | Professor of Addiction Neuroscience | University of Cambridge |
| Dr Sarah Flowers | Consultant Addiction Psychiatrist | Sussex Partnership NHS Foundation Trust |
| Ms Nuala Foley | Associate Director Commercial and Enterprise | Kent Surrey and Sussex Academic Health Science Network |
| Miss Helen George | PPI Representative | PPI Representative |
| Mr Justin Greenwood | PPI Representative | PPI Representative |
| Professor Magdalena Harris | Associate Professor | London School of Hygiene and Tropical Medicine |
| Professor Stephen Ong | Programme Manager | South West Academic Health Science Network |
| Professor Duncan Stewart | Professor, Centre for Primary Health and Social Care | London Metropolitan University |
| Dr Pauline Whelan | Co-Director GM.Digital; Information Systems Programme Manager | The University of Manchester |
Minutes for the i4i Addiction Mission: Innovation for Treatment and Recovery Awards (AMI) Stage 1 Committee Meeting
Date and Location
Wednesday 02 August 2023 via Zoom Virtual Meeting
In attendance
Committee members
Professor David Nutt (Deputy Chair)
Professor Karen D Ersche
Ms Nuala Foley
Dr Pauline Whelan
Secretariat
Professor Mike Lewis (Programme Director)
Dr Rafaella Roncone (NIHRCC)
Mr Stuart Haylock (NIHRCC)
Ms Amy Muggeridge (NIHRCC)
Ms Cordelia Davey Wright (NIHRCC)
Ms Elena Sundle (NIHRCC)
Apologies
Dr Joe Tay Wee Teck
Dr Ilana Belle Crome
Ms Jenny Chong
Professor Barry John Everitt
Professor Magdalena Harris
Professor Vivian David Hope
Professor Celia J A Morgan
Professor Duncan Stewart
Professor Kim Wolff
Observers
Erinn Melville (OLS)
Stage 1 applications invited to submit to Stage 2:
NIHR206621: MEDICATIONS FOR COCAINE USE DISORDER (MEDCO): A DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE TWO TRIAL
Outcome: Invite to Stage 2
NIHR206657: Buprenorphine Induction Low-Dose to Depot (BUILD2depot): development of safe rapid transfer to depot medication and Go/NoGo testing potential of remote community-based monitoring.
Outcome: Invite to Stage 2
NIHR206685: The feasibility and acceptability of the Mindfulness Orientated Recovery Enhancement Virtual Reality intervention in adults undergoing an opioid substitution therapy dose reduction or detoxification in an inpatient setting (Inpatient MORE-VR).
Outcome: Invite to Stage 2
NIHR206692: Prison Release Engagement Trial (PRET): Randomised trial of App-coordinated daily bot contact to improve prison-release continuity of care: testing engagement with OST medication-assisted treatment or medication-free support.
Outcome: Invite to Stage 2
NIHR206697: Testing locality-wide Contingency Management Incentive Manager (CMIM): does app-coordinated application of CM improve individual achievement of drug abstinence by cocaine and opioid users?
Outcome: Invite to Stage 2
NIHR206721: Development, evaluation and testing of a Virtual Reality-enhanced Cue Exposure Treatment integrated with a wearable device to address craving, prevent relapse and improve treatment outcomes of people with cocaine dependence.
Outcome: Invite to Stage 2
NIHR206730: Applying the REC-CAP (online recovery capital measurement and management tool) in recovery settings in the UK
Outcome: Invite to Stage 2
NIHR206736: A Phase 2a dose ascending, placebo randomised controlled trial, to investigate psilocybin therapy and brain reward mechanisms in opiate use disorder (OUD).
Outcome: Invite to Stage 2
Stage 1 applications not invited to submit to Stage 2:
NIHR206686: A double-blind feasibility and proof-of-concept randomised trial of aprepitant for the management of heroin and cocaine use in methadone-maintained opioid use disorder
Outcome: Reject
NIHR206689: Digitising the Treatment Outcome Profile (TOP) form at point of care to improve drug treatment progress. Developing analytics and machine learning for caseload management and risk predictors of treatment outcomes.
Outcome: Reject
NIHR206693: Ketamine And Memory Reconsolidation Interference For Prescription Opiate-use Disorders (KAMRIPOD)
Outcome: Reject
NIHR206713: The use of Ecological Momentary Assessments (EMA) to remotely assess and monitor the readiness of patients to complete detoxification from long-acting injectable buprenorphine.
Outcome: Reject
NIHR206716: Using Virtual Reality (VR) to support delivery of drug addiction programmes working in partnership with service users? (VANISH)
Outcome: Reject
NIHR206723: Simplyworks - creating sustainable engagement. Addiction is an isolating condition, the proposed research is to use a digital peer support system to reduce isolation and enhance support
Outcome: Reject
NIHR206725: The Better Outcomes for Opioid Treatment (BOOT) Project
Outcome: Reject
NIHR206726: Developing a virtual reality intervention for people in recovery from opiate and cocaine addiction
Outcome: Reject
NIHR206747: Proposal for Personalised Opioid Dispenser to Enhance Treatment and Recovery from Addiction
Outcome: Reject
NIHR206752: Utilising Digital Therapeutics (DTx) in combination with Wearables and Positive rewards for personalised substance abuse therapy for Cocaine addiction
Outcome: Reject
NIHR206753: Using digital real-time feedback tools to improve treatment effectiveness for crack cocaine and opioid users in community treatment – a stepped-wedge cluster randomised trial (SW-CRT)
Outcome: Reject
Stage 1 applications that did not fulfill the Programmes eligibility criteria:
NIHR206751: Prevention of fatal drug-drug interactions between illicit substances and prescribed pharmaceutical medicines
Outcome: Reject
Minutes for the i4i Addiction Mission: Innovation for Treatment and Recovery Awards (AMI) Stage 2 Committee Meeting
Date and Location
Wednesday 06 December 2023 via Zoom Virtual Meeting
In attendance
Committee members
Professor David Nutt (Chair)
Professor Celia J A Morgan (Deputy Chair)
Ms Jenny Chong
Dr Oscar D'agnone
Professor Karen D Ersche
Dr Sarah Flowers
Ms Nuala Foley
Mrs Helen George
Mr Justin Greenwood
Professor Magdalena Harris
Professor Duncan Stewart
Professor Stephen Ong
Dr Pauline Whelan
Secretariat
Professor Mike Lewis (Programme Director)
Dr Rafaella Roncone (NIHRCC)
Mr Stuart Haylock (NIHRCC)
Ms Amy Muggeridge (NIHRCC)
Ms Cordelia Davey Wright (NIHRCC)
Ms ElenaSundle (NIHRCC)
Ms Holly Rabjohns Wright (NIHRCC)
Mr Noor Akbar (NIHRCC)
Observers
Dr Tom Dalliston (OLS)
Ms Erinn Melville (OLS)
Professor Anne Lingford-Hughes (OLS)
Applications assessed at Stage 2:
NIHR206621: MEDICATIONS FOR COCAINE USE DISORDER (MEDCO): A DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE TWO TRIAL
Conflicted Committee Members: Professor Magdalena Harris, Professor Duncan Stewart
Funding Committee recommendation: Reject
NIHR206657: Buprenorphine Induction Low-Dose to Depot (BUILD2depot): development of safe rapid transfer to depot medication and Go/NoGo testing potential of remote community-based monitoring.
Conflicted Committee Members: Professor Magdalena Harris, Professor Duncan Stewart, Professor Anne Lingford-Hughes
Funding Committee recommendation: Support
NIHR206736: A Phase 2a dose ascending, placebo randomised controlled trial, to investigate psilocybin therapy and brain reward mechanisms in opiate use disorder (OUD).
Conflicted Committee Members: Professor David Nutt, Professor Magdalena Harris, Professor Anne Lingford-Hughes
Funding Committee recommendation: Support
NIHR206692: Prison Release Engagement Trial (PRET): Randomised trial of App-coordinated daily bot contact to improve prison-release continuity of care: testing engagement with OST medication-assisted treatment or medication-free support.
Conflicted Committee Members: Professor Magdalena Harris, Professor Duncan Stewart, Professor Anne Lingford-Hughes
Funding Committee recommendation: Support
NIHR206697: Testing locality-wide Contingency Management Incentive Manager (CMIM): does app-coordinated application of CM improve individual achievement of drug abstinence by cocaine and opioid users?
Conflicted Committee Members: Professor Magdalena Harris, Professor Duncan Stewart, Professor Anne Lingford-Hughes
Funding Committee recommendation: Reject
NIHR206721: Development, evaluation and testing of a Virtual Reality-enhanced Cue Exposure Treatment integrated with a wearable device to address craving, prevent relapse and improve treatment outcomes of people with cocaine dependence.
Conflicted Committee Members: Professor Karen D Ersche, Professor Duncan Stewart, Dr Pauline Whelan, Professor Anne Lingford-Hughes
Funding Committee recommendation: Support
NIHR206730: Applying the REC-CAP (online recovery capital measurement and management tool) in recovery settings in the UK
Conflicted Committee Members: Mr Justin Greenwood, Professor Duncan Stewart
Funding Committee recommendation: Reject
NIHR206685: The feasibility and acceptability of the Mindfulness Orientated Recovery Enhancement Virtual Reality intervention in adults undergoing an opioid substitution therapy dose reduction or detoxification in an inpatient setting (Inpatient MORE-VR).
Conflicted Committee Members: Professor Celia J A Morgan, Dr Pauline Whelan, Professor Anne Lingford-Hughes
Funding Committee recommendation: Reject